SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ALL who wrote (4052)4/15/1998 8:34:00 AM
From: Henry Niman  Read Replies (1) of 6136
 
Here's what BancAmerca Robertson Stephens had to say:
Key Points:
ú New protease inhibitor scrips were up 8.9% over last week's level. Agouron's market
share of new protease inhibitor prescriptions was 30.6%, unchanged from 30.6% last
week.
ú Total protease inhibitor scrips were up 6.5%, and Agouron's market share was 30.7%,
up from 30.2% the week prior.
ú Refill protease inhibitor scrips were up 5.1% versus last week. Viracept's market share
of refills was 30.8% for the week of April 3 (it had been 30.0% for the week of March
27).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News